Viridian Therapeutics, Inc.
VRDNDrugs in Pipeline
5
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How VRDN's past catalysts played out
VRDN-001 10 mg/kg
Thyroid Eye Disease
Intervention/Treatment
Thyroid Eye Disease
VRDN-001 Phase 3 Cohort (THRIVE)
Thyroid Eye Disease
Veligrotug (VRDN-001)
Thyroid Eye Disease
VRDN-003
Thyroid Eye Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VRDN-001 10 mg/kg | Phase 3 | Thyroid Eye Disease | - | - |
Intervention/Treatment | Phase 3 | Thyroid Eye Disease | - | - |
VRDN-001 Phase 3 Cohort (THRIVE) | Phase 3 | Thyroid Eye Disease | - | - |
Veligrotug (VRDN-001) | Phase 3 | Thyroid Eye Disease | - | - |
VRDN-003 | Phase 3 | Thyroid Eye Disease | - | - |
Frequently asked questions
What is in Viridian Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Viridian Therapeutics, Inc.'s (VRDN) pipeline across Phase 3. Its lead program is VRDN-001 10 mg/kg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Viridian Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Viridian Therapeutics, Inc. (VRDN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track VRDN biotech catalysts?→
Add VRDN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Viridian Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.